Alex Gorsky to Step Down After 30-Year Career
at Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) today announced that its Board
of Directors has elected Chief Executive Officer, Mr. Joaquin
Duato, to assume the additional position of Chairman, effective in
January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step
down from his role as Executive Chairman following a brief
transitional period.
Mr. Duato has served as Johnson & Johnson’s CEO and a member
of the Board of Directors since January 3, 2022. Prior to that
time, he held senior leadership positions over his 30-plus year
career with the Company across multiple business sectors,
geographics and functions.
“On behalf of the Board of Directors, I would like to thank Alex
for his unwavering commitment to Johnson & Johnson. Over the
last three decades, Alex’s influence has truly shaped the global
healthcare landscape and improved billions of lives,” said Anne
Mulcahy, Lead Independent Director. “Joaquin’s appointment to the
additional role of Chairman reflects his tremendous 30-year track
record at Johnson & Johnson, as well as the Board’s thoughtful
and engaged approach to succession planning. During Joaquin’s
career with the Company, the Board has witnessed firsthand his
ability to effectively lead, collaborate, and create value for all
our stakeholders. We have the utmost confidence that he will
continue to be an excellent steward of the business and look
forward to working closely with him in this next chapter.”
Mr. Duato said, “Guided by our Credo, I will continue to work
closely with the other Directors to build on Johnson &
Johnson’s success. I also want to thank Alex for his countless
contributions to our Company. He has inspired an entire generation
of leaders with his passion for improving human health, built the
best team in the industry and laid a strong foundation for the
future of both Johnson & Johnson and Kenvue, the planned new
Consumer Health company.”
“The opportunity to lead Johnson & Johnson through such a
pivotal time in the Company’s history has been the great privilege
of my life,” said Alex Gorsky. “I would like to express my deep
appreciation to every employee, past and present, for their
steadfast commitment to bringing our Credo to life every day and to
improving the well-being of those who rely on us. It has been an
honor to work alongside each of you, and I could not think of a
better leader than Joaquin to lead the Board as it helps guide the
Company to even greater achievements.”
About Joaquin Duato Joaquin Duato is the Chief Executive
Officer of Johnson & Johnson and serves on its Board of
Directors. He leads a global workforce of 135,000 employees in
developing and delivering transformational and innovative
healthcare solutions in Pharmaceuticals, MedTech, and Consumer
Health. Previously, Joaquin served as the Vice Chairman of the
Executive Committee, where he provided strategic direction for the
Pharmaceutical and Consumer Health sectors and oversaw both
Information Technology and the Global Supply Chain.
A believer in the power of technology to accelerate progress in
healthcare, Joaquin is leading Johnson & Johnson to harness
data science and intelligent automation to solve the world’s
toughest health challenges. He is committed to building an
inclusive workforce that reflects the patients Johnson &
Johnson serves.
He earned an MBA from ESADE in Barcelona, Spain, and a Master of
International Management from Thunderbird School of Global
Management in Phoenix, Arizona.
About Alex Gorsky Alex Gorsky is Chairman of the Board
and Chief Executive Officer of Johnson & Johnson, one of just
seven leaders who have served in the dual role since the company
was listed on the New York Stock Exchange in 1944.
Alex began his Johnson & Johnson career as a sales
representative with Janssen Pharmaceutica in 1988. Over the next
three decades, he advanced through positions of increasing
responsibility in sales, marketing, and management, culminating in
being named CEO and Chairman in 2012. Under Alex’s leadership,
Johnson & Johnson continues to be one of the world’s
exceptional corporations and is currently the number one
pharmaceutical company on Fortune magazine’s list of the “World’s
Most Admired Companies.”
A longtime advocate of diversity and inclusion and supporter of
veterans’ issues, Alex currently sits on the Board of Directors of
Apple, IBM, JPMorgan Chase, NewYork-Presbyterian Hospital, and the
Travis Manion Foundation, and serves on the Wharton School of the
University of Pennsylvania Board of Advisors.
After completing his undergraduate education at the U.S.
Military Academy at West Point, NY, Alex served six years in the
Army. He earned his MBA from the Wharton School of the University
of Pennsylvania in 1996.
About Johnson & Johnson At Johnson & Johnson, we
believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That’s why for more than 135
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world’s largest diversified healthcare
products company, we are committed to using our reach and size for
good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as
defined in the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson
& Johnson. Risks and uncertainties include, but are not limited
to: economic factors, such as interest rate and currency exchange
rate fluctuations; competition, including technological advances,
new products and patents attained by competitors; challenges
inherent in new product research and development, including
uncertainty of clinical success and obtaining regulatory approvals;
uncertainty of commercial success for new and existing products;
challenges to patents; the impact of patent expirations; the
ability of the Company to successfully execute strategic plans; the
impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or
regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to
applicable laws and regulations, including tax laws and global
health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health
care products and services; financial instability of international
economies and legal systems and sovereign risk; increased scrutiny
of the health care industry by government agencies. A further list
and descriptions of these risks, uncertainties and other factors
can be found in Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended January 2, 2022, including in the
sections captioned “Cautionary Note Regarding Forward-Looking
Statements” and “Item 1A. Risk Factors,” in the Company’s most
recently filed Quarterly Report on Form 10-Q and the Company’s
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. Any
forward-looking statement made in this release speaks only as of
the date of this release. Johnson & Johnson does not undertake
to update any forward-looking statement as a result of new
information or future events or developments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221130006118/en/
Media: Jake Sargent jsargen3@its.jnj.com
Investor Relations: Jessica Moore
jmoore29@its.jnj.com
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024